表紙
市場調查報告書
商品編碼
1024235

肌肉萎縮性側索硬化症:現在及今後的市場機會,流行病學研究,市場動態,開發平台分析,r-NPV分析

Amyotrophic Lateral Sclerosis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 215 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供肌肉萎縮性側索硬化症的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病的概要與流行病學研究

第4章 肌肉萎縮性側索硬化症的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 肌肉萎縮性側索硬化症競爭空間的交易活動

第7章 肌肉萎縮性側索硬化症管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH520

GervanoRA's pipeline analysis and opportunity assessment report "Amyotrophic Lateral Sclerosis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Amyotrophic Lateral Sclerosis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Amyotrophic Lateral Sclerosis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Amyotrophic Lateral Sclerosis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Amyotrophic Lateral Sclerosis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Amyotrophic Lateral Sclerosis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Amyotrophic Lateral Sclerosis Market (2020) and the Forecasted Amyotrophic Lateral Sclerosis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Amyotrophic Lateral Sclerosis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Amyotrophic Lateral Sclerosis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Amyotrophic Lateral Sclerosis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: AMYOTROPHIC LATERAL SCLEROSIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF AMYOTROPHIC LATERAL SCLEROSIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF AMYOTROPHIC LATERAL SCLEROSIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: TOP 10 DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS RANKED BY DEAL AMOUNT
  • TABLE 03: MAJOR COLLABORATIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 04: MAJOR MERGERS AND ACQUISITIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 05: MAJOR FINANCING DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 06: MAJOR LICENSING DEALS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • TABLE 07: PATENT PORTFOLIO OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 08: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
  • TABLE 09: AMYOTROPHIC LATERAL SCLEROSIS PRE - REGISTRATION CANDIDATES
  • TABLE 10: PHASE 3 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 11: PHASE 2 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 12: PHASE 1 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 13: PRECLINICAL MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 14: EARLY R&D MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 15: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 16: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY INJECTABLE AS ROA
  • TABLE 17: CELL THERAPIES AND GENE THERAPIES UNDER DEVELOPMENT FOR ALS
  • TABLE 18: UNIVERSITY'S PIPELINE MOLECULES FOR ALS
  • TABLE 19: ESTIMATED APPROVAL TIMELINES OF ALS PIPELINE DRUGS
  • TABLE 20: EXTERNAL FUNDING RECEIVED BY TOP EMERGING COMPANIES (RANKED LEAST TO MAXIMUM)

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN ALS AREA, 2021-2030
  • FIGURE 02: GENETICS OF ALS
  • FIGURE 03: ALS EPIDEMIOLOGY FORECAST (2019-2025), US
  • FIGURE 04: ALS EPIDEMIOLOGY FORECAST (2019-2025), EUROPE
  • FIGURE 05: AMYOTROPHIC LATERAL SCLEROSIS DEALS, BY DEAL TYPE
  • FIGURE 06: AMYOTROPHIC LATERAL SCLEROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT ($M)
  • FIGURE 07: AMYOTROPHIC LATERAL SCLEROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 08: YEAR WISE SPLIT-UP OF COLLABORATIONS IN THE AMYOTROPHIC LATERAL SCLEROSIS AREA
  • FIGURE 09: NUMBER OF AMYOTROPHIC LATERAL SCLEROSIS DEALS, YEAR BY YEAR
  • FIGURE 10: PIPELINE MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS AREA, PERCENT SHARE
  • FIGURE 11: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE SPLIT BY GEOGRAPHY, NUMBER OF EXPECTED DRUG APPROVALS
  • FIGURE 12: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 13: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 14: ORALS BY HSD SPLIT-UP
  • FIGURE 15: INJECTABLES BY HSD SPLIT-UP